Statistical Optimization Of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis

Current Pharmacogenomics and Personalized Medicine

Volumn 9, Issue 1, 2011, Pages 41-66

  Grady, Benjamin J ^a   Ritchie, Marylyn D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Epistasis; Genotyping; Personalized medicine; Pharmacogenomics; Quality control; Statistics; Study design

Indexed keywords

CASE CONTROL STUDY; COHORT ANALYSIS; DRUG RESPONSE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC EPISTASIS; GENOTYPE; HUMAN; PHARMACOGENOMICS; PROCESS OPTIMIZATION; PUBLIC HEALTH SERVICE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STUDY DESIGN; VALIDATION PROCESS;

EID: 79952763405     PISSN: 18756921     EISSN: 18756913     Source Type: Journal    
DOI: 10.2174/187569211794728805     Document Type: Review

References (226)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279(15): 1200-5.
2. Botstein D, White RL, Skolnick M, et al. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet 1980; 32(3): 314-31.
3. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989; 44: 388-96.
4. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science 1997; 278(5343): 1580-1.
5. Durbin RM, Abecasis GR, Altshuler DL, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467(7319): 1061-73.
6. Sebat J, Lakshmi B, Troge J, et al. Large-scale copy number polymorphism in the human genome. Science 2004; 305(5683): 525-8.
7. Joober R, Boksa P. A new wave in the genetics of psychiatric disorders: the copy number variant tsunami. J Psychiatry Neurosci 2009; 34(1): 55-9.
8. Collins FS, Morgan M, Patrinos A. The Human Genome Project: lessons from large-scale biology. Science 2003; 300(5617): 286-90.
9. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409(6822): 860-921.
10. International hapmap consortium. The International HapMap Project. Nature 2003; 426(6968): 789-96.
11. International hapmap consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449(7164): 851-61.
12. Slatkin M. Linkage disequilibrium--understanding the evolutionary past and mapping the medical future. Nat Rev Genet 2008; 9(6): 477-85.
13. Lander ES. The new genomics: global views of biology. Science 1996; 274(5287): 536-9.
14. Haines JL, Pericak-Vance MA. Genetic Analysis of Complex Disease. Hoboken, NJ: John Wiley & Sons. 2006.
15. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009; 106(23): 9362-7.
16. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008; 118(5): 1590-605.
17. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med 2010; 363(2): 166-76.
18. Botstein D, Risch N. Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet 2003; (Suppl 33): 228-37.
19. Carlson CS, Eberle MA, Kruglyak L, et al. Mapping complex disease loci in whole-genome association studies. Nature 2004; 429(6990): 446-52.
20. Maher B. Personal genomes: The case of the missing heritability. Nature 2008; 456(7218): 18-21.
21. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261(5123): 921-3.
22. Pericak-Vance MA, Bebout JL, Gaskell PC, et al. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am J Hum Genet 1991; 48(6): 1034-50.
23. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308(5720): 419-21.
24. Edwards AO, Ritter R 3rd, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308(5720): 421-4.
25. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308(5720): 385-9.
26. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010; 68(2): 270-81.
27. Schork NJ, Murray SS, Frazer KA, et al. Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev 2009; 19(3): 212-9.
28. Via M, Gignoux C, Burchard EG. The 1000 Genomes Project: new opportunities for research and social challenges. Genome Med 2010; 2(1): 3.
29. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009; 461(7265): 747-53.
30. Phillips PC. Epistasis--the essential role of gene interactions in the structure and evolution of genetic systems. Nat Rev Genet 2008; 9(11): 855-67.
31. Bateson W. Mendel's Principles of Heredity. Cambridge: Cambridge University Press. 1909.
32. Barbaric I, Miller G, Dear TN. Appearances can be deceiving: phenotypes of knockout mice. Brief Funct Genomic Proteomic 2007; 6(2): 91-103.
33. Franz T, Winckler L, Boehm T, et al. Capn5 is expressed in a subset of T cells and is dispensable for development. Mol Cell Biol 2004; 24(4): 1649-54.
34. Giaever G, Chu AM, Ni L, et al. Functional profiling of the Saccharomyces cerevisiae genome. Nature 2002; 418(6896): 387-91.
35. Smith V, Chou KN, Lashkari D, et al. Functional analysis of the genes of yeast chromosome V by genetic footprinting. Science 1996; 274(5295): 2069-74.
36. Winzeler EA, Shoemaker DD, Astromoff A, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 1999; 285(5429): 901-6.
37. Bouche N, Bouchez D. Arabidopsis gene knockout: phenotypes wanted. Curr Opin Plant Biol 2001; 4(2): 111-7.
38. Bondos SE, Catanese DJ Jr, Tan XX, et al. Hox transcription factor ultrabithorax Ib physically and genetically interacts with disconnected interacting protein 1, a double-stranded RNA-binding protein. J Biol Chem 2004; 279(25): 26433-44.
39. Rain JC, Selig L, De RH, et al. The protein-protein interaction map of Helicobacter pylori. Nature 2001; 409(6817): 211-5.
40. Culverhouse R, Suarez BK, Lin J, et al. A perspective on epistasis: limits of models displaying no main effect. Am J Hum Genet 2002; 70(2): 461-71.
41. Lay-Son G, Puga A, Astudillo P, et al. Cystic fibrosis in Chilean patients: Analysis of 36 common CFTR gene mutations. J CystFibros 2011; 10(1): 66-70.
42. Bibi Z. Role of cytochrome P450 in drug interactions. Nutr Metab(Lond) 2008; 5: 27.
43. Ekbal NJ, Holt DW, Macphee IA. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients. Pharmacogenomics 2008; 9(5): 585-96.
44. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
45. Taubert D, Bouman HJ, van Werkum JW. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360(21): 2249-50.
46. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360(4): 354-62.
47. James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45(8): 704-6.
48. Tan GM, Wu E, Lam YY, et al. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 2010; 11(3): 439-48.
49. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353(9154): 717-9.
50. Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol 2010; 63(9): 960-9.
51. Oldenburg J, Bevans CG, Muller CR, et al. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 2006; 8(3-4): 347-53.
52. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358(6): 568-79.
53. The Merck Manuals Online Medical Library. Pharmacokinetics. 2010. Available from: http://www.merck.com/mmpe/sec20/ch303/ch303a.html [Accessed January 17, 2011].
54. Dahlin MG, Beck OM, Amark PE. Plasma levels of antiepileptic drugs in children on the ketogenic diet. Pediatr Neurol 2006; 35(1): 6-10.
55. Ohara K, Tanabu S, Ishibashi K, et al. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003; 58(10): 659-61.
56. Singh R, Srivastava A, Kapoor R, et al. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 2009; 380(2): 169-77.
57. The pharmacokinetics working group of the AGAH. Collection of terms, symbols, equations, and explanations of common pharmacokinetic and pharmacodynamic parameters and some statistical functions. 2004. Available from: http://www.agah.info/uploads/media/PK-glossary_PK_working_group_2004_01.pdf [Accessed January 17, 2011].
58. The Merck Manuals Online Medical Library. Pharmacodynamics. 2010. Available from: http://www.merck.com/mmpe/sec20/ch304/ch304a.html [Accessed January 17, 2011].
59. Majumder PP, Ghosh S. Mapping quantitative trait loci in humans: achievements and limitations. J Clin Invest 2005; 115(6): 1419-24.
60. Ghosh S. Genome-wide association analyses of quantitative traits: the GW16 experience. Genet Epidemiol 2009; 33(Suppl 1): S13-8.
61. Turner SD, Crawford DC, Ritchie MD. Methods for optimizing statistical analyses in pharmacogenomics research. Expert Rev Clin Pharmacol 2009; 2(5): 559-70.
62. Fredrickson DS, Lees RS. A System For Phenotyping Hyperlipoproteinemia. Circulation 1965; 31: 321-7.
63. Crum-Cianflone NF, Grandits G, Echols S, et al. Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use? J Acquir Immune Defic Syndr 2010; 54(3): 248-57.
64. Ginsburg GS, Voora D. The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 2010; 55(25): 2813-5.
65. Kiyotani K, Mushiroda T, Hosono N, et al. Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet Genomics 2010; 20(9): 565-8.
66. Chen MH, Tzeng CH, Chen PM, et al. VEGF -460T --> C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenomics J 2010; [Epub ahead of print].
67. Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 2004; 18(5): 259-73.
68. Jiang H, Fine JP. Survival analysis. Methods Mol Biol 2007; 404: 303-18.
69. Schlesselman JJ. Case-Control Studies. Design, Conduct, Analysis. New York/Oxford: Oxford University Press. 1982.
70. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7(10): 781-91.
71. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the value of prospective cohort studies. Nat Rev Genet 2006; 7(10): 812-20.
72. Thomas DC. Statistical Methods in Genetic Epidemiology. New York, NY: Oxford University Press, Inc. 2004.
73. Little J, Sharp L, Khoury MJ, et al. The epidemiologic approach to pharmacogenomics. Am J Pharmacogenomics 2005; 5(1): 1-20.
74. Stolberg HO, Norman G, Trop I. Randomized controlled trials. AJR Am J Roentgenol 2004; 183(6): 1539-44.
75. Jadad AR. Randomised controlled trials: a user's guide. London, England: BMJ Books. 1998.
76. Smith PG, Day NE. The design of case-control studies: the influence of confounding and interaction effects. Int J Epidemiol 1984; 13: 356-65.
77. Zang EA, Wynder EL. Reevaluation of the confounding effect of cigarette smoking on the relationship between alcohol use and lung cancer risk, with larynx cancer used as a positive control. Prev Med 2001; 32(4): 359-70.
78. Hoggart CJ, Parra EJ, Shriver MD, et al. Control of confounding of genetic associations in stratified populations. Am J Hum Genet 2003; 72(6): 1492-504.
79. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312(7040): 1215-8.
80. Sanson-Fisher RW, Bonevski B, Green LW, et al. Limitations of the randomized controlled trial in evaluating population-based health interventions. Am J Prev Med 2007; 33(2): 155-61.
81. Haas DW. Human genetic variability and HIV treatment response. Curr HIV /AIDS Rep 2006; 3(2): 53-8.
82. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: casecontrol studies with no controls! Am J Epidemiol 1996; 144(3): 207-13.
83. Vander Weele TJ, Hernandez-Diaz S, Hernan MA. Case-only gene-environment interaction studies: when does association imply mechanistic interaction? Genet Epidemiol 2010; 34(4): 327-34.
84. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008; 9(5): 356-69.
85. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet 2003; 4: 293-340.
86. Hindorff LA, Junkins HA, Hall PN et al. A Catalog of Published Genome-Wide Association Studies. 2010. Available from: www.genome.gov/gwastudies [Accessed January 17, 2011].
87. Niculescu AB, Le-Niculescu H. The P-value illusion: how to improve (psychiatric) genetic studies. Am J Med Genet B Neuropsychiatr Genet 2010; 153B(4): 847-9.
88. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National MultipleSclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46(4): 907-11.
89. Hoffjan S, Akkad DA. The genetics of multiple sclerosis: An update 2010. Mol Cell Probes 2010; 24(5): 237-43.
90. McClellan J, King MC. Genetic heterogeneity in human disease. Cell 2010; 141(2): 210-7.
91. Pilgrim JL, Gerostamoulos D, Drummer OH. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Sci Med Pathol 2010[Epub ahead of print].
92. Yap TA, Sandhu SK, Workman P, et al. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10(7): 514-23.
93. Chanock SJ, Manolio T, Boehnke M, et al. Replicating genotypephenotype associations. Nature 2007; 447(7145): 655-60.
94. Burmester JK, Sedova M, Shapero MH, et al. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol 2010; 632: 99-124.
95. Talmud PJ, Drenos F, Shah S, et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet 2009; 85(5): 628-42.
96. Roeder K, Bacanu SA, Wasserman L, et al. Using linkage genome scans to improve power of association in genome scans. Am J Hum Genet 2006; 78(2): 243-52.
97. Saccone SF, Bierut LJ, Chesler EJ, et al. Supplementing highdensity SNP microarrays for additional coverage of disease-related genes: addiction as a paradigm. PLoS One 2009; 4(4): e5225.
98. Sissung TM, English BC, Venzon D, et al. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 2010; 11(1): 89-103.
99. Chuang LY, Yang CS, Ho CH, et al. Tag SNP selection using particle swarm optimization. Biotechnol Prog 2010; 26(2): 580-8.
100. Han B, Kang HM, Seo MS, et al. Efficient association study design via power-optimized tag SNP selection. Ann Hum Genet 2008; 72(Pt 6): 834-47.
101. Li J. Prioritize and select SNPs for association studies with multistage designs. J Comput Biol 2008; 15(3): 241-57.
102. Pico AR, Smirnov IV, Chang JS, et al. SNPLogic: an interactive single nucleotide polymorphism selection, annotation, and prioritization system. Nucleic Acids Res 2009; 37(Database issue): D803-D809.
103. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 2002; 3(5): 391-7.
104. Allegue C, Gil R, Sanchez-Diz P, et al. A new approach to long QT syndrome mutation detection by Sequenom MassARRAY system. Electrophoresis 2010; 31(10): 1648-55.
105. Oberst RD, Hays MP, Bohra LK, et al. PCR-based DNA amplification and presumptive detection of Escherichia coli O157:H7 with an internal fluorogenic probe and the 5' nuclease (TaqMan) assay. Appl Environ Microbiol 1998; 64(9): 3389-96.
106. Steemers FJ, Gunderson KL. Illumina, Inc. Pharmacogenomics 2005; 6(7): 777-82.
107. Macphee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4(6): 914-9.
108. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90(16): 1225-9.
109. St George-Hyslop P. Molecular genetics of Alzheimer's disease. Biol Psychiatry 2000; 47(3): 183-99.
110. Finishing the euchromatic sequence of the human genome. Nature 2004; 431(7011): 931-45.
111. Pushkarev D, Neff NF, Quake SR. Single-molecule sequencing of an individual human genome. Nat Biotechnol 2009; 27(9): 847-52.
112. Kedes L, Liu ET. The Archon Genomics X PRIZE for whole human genome sequencing. Nat Genet 2010; 42(11): 917-8.
113. Mardis ER. Anticipating the 1,000 dollar genome. Genome Biol 2006; 7(7): 112.
114. Bonetta L. Whole-genome sequencing breaks the cost barrier. Cell 2010; 141(6): 917-9.
115. Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 2009; 106(45): 19096-101.
116. Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature 2009; 461(7261): 272-6.
117. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26(10): 1135-45.
118. Hosseini P, Tremblay A, Matthews BF, et al. An efficient annotation and gene-expression derivation tool for Illumina Solexa datasets. BMC Res Notes 2010; 3: 183.
119. Koboldt DC. Challenges of sequencing human genomes. Brief Bioinform 2010; 11(5): 484-98.
120. Korbel JO, Urban AE, Grubert F, et al. Systematic prediction and validation of breakpoints associated with copy-number variants in the human genome. Proc Natl Acad Sci USA 2007; 104(24): 10110-5.
121. Weale ME. Quality control for genome-wide association studies. Methods Mol Biol 2010; 628: 341-72.
122. Laurie CC, Doheny KF, Mirel DB, et al. Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol 2010; 34(6): 591-602.
123. Turner SD, Armstrong LL, Bradford Y, et al. Quality Control Procedures for Genome Wide Association Studies. Current Protocols 2010; In press.
124. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81(3): 559-75.
125. Grady BJ, Torstenson E, Dudek SM, et al. Finding unique filter sets in plato: a precursor to efficient interaction analysis in gwas data. Pac Symp Biocomput 2010; 315-26.
126. Aulchenko YS, Ripke S, Isaacs A, et al. GenABEL: an R library for genome-wide association analysis. Bioinformatics 2007; 23(10): 1294-6.
127. Thornton T, McPeek MS. Case-control association testing with related individuals: a more powerful quasi-likelihood score test. Am J Hum Genet 2007; 81(2): 321-37.
128. Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 2010; 11: 134.
129. Voight BF, Pritchard JK. Confounding from cryptic relatedness in case-control association studies. PLoS Genet 2005; 1(3): e32.
130. Wittke-Thompson JK, Pluzhnikov A, Cox NJ. Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76(6): 967-86.
131. Hardy GH. Mendelian Proportions in a Mixed Population. Science 1908; 28(706): 49-50.
132. Edenberg HJ, Liu Y. Laboratory methods for high-throughput genotyping. Cold Spring Harb Protoc 2009; 2009(11): pdb.top62.
133. Pluzhnikov A, Below JE, Konkashbaev A, et al. Spoiling the whole bunch: quality control aimed at preserving the integrity of highthroughput genotyping. Am J Hum Genet 2010; 87(1): 123-8.
134. Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010; 11(10): 733-9.
135. Sebastiani P, Solovieff N, Puca A, et al. Genetic Signatures of Exceptional Longevity in Humans. Science 2010, [Epub ahead of print].
136. Alberts B. Editorial expression of concern. Science 2010; 330(6006): 912.
137. 23andMe. SNPwatch: Uncertainty Surrounds Longevity GWAS. 2010. Available from: http://spittoon.23andme.com/2010/07/07/snpwatch-uncertainty-surrounds-longevity-gwas/ [Accessed January 17, 2011].
138. Tian C, Gregersen PK, Seldin MF. Accounting for ancestry: population substructure and genome-wide association studies. Hum Mol Genet 2008; 17(R2): R143-R150.
139. Pritchard JK, Rosenberg NA. Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65(1): 220-8.
140. Montana G, Pritchard JK. Statistical tests for admixture mapping with case-control and cases-only data. Am J Hum Genet 2004; 75(5): 771-89.
141. Ribaudo HJ, Liu H, Schwab M, et al. Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study. J Infect Dis 2010; 202(5): 717-22.
142. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001; 69(1): 24-31.
143. Cavallari LH, Langaee TY, Momary KM, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87(4): 459-64.
144. Epstein MP, Allen AS, Satten GA. A simple and improved correction for population stratification in case-control studies. Am J Hum Genet 2007; 80(5): 921-30.
145. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999; 55(4): 997-1004.
146. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38(8): 904-9.
147. Pritchard JK, Stephens M, Rosenberg NA, et al. Association mapping in structured populations. Am J Hum Genet 2000; 67(1): 170-81.
148. Satten GA, Flanders WD, Yang Q. Accounting for unmeasured population substructure in case-control studies of genetic association using a novel latent-class model. Am J Hum Genet 2001; 68(2): 466-77.
149. Barnholtz-Sloan JS, Chakraborty R, Sellers TA, et al. Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol Biomarkers Prev 2005; 14(6): 1545-51.
150. Tian C, Kosoy R, Nassir R, et al. European population genetic substructure: further definition of ancestry informative markers for distinguishing among diverse European ethnic groups. Mol Med 2009; 15(11-12): 371-83.
151. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155(2): 945-59.
152. Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: Areview of statistical methods and recommendations for their application. Am J Hum Genet 2010; 86(1): 6-22.
153. Greenwood PE, Nikulin MS. A guide to chi-squared testing. New York: Wiley. 1996.
154. Zheng HX, Webber SA, Zeevi A, et al. The impact of pharmacogenomic factors on steroid dependency in pediatric hearttransplant patients using logistic regression analysis. Pediatr Transplant 2004; 8(6): 551-7.
155. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955; 11: 375-86.
156. Cree BA, Rioux JD, McCauley JL, et al. A major histocompatibility Class I locus contributes to multiple sclerosis susceptibility independently from HLA-DRB1*15:01. PLoS One 2010; 5(6): e11296.
157. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958; 53: 457-81.
158. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009; 19(3): 226-34.
159. Stephens M, Balding DJ. Bayesian statistical methods for genetic association studies. Nat Rev Genet 2009; 10(10): 681-90.
160. Coassin S, Brandstatter A, Kronenberg F. Lost in the space of bioinformatic tools: a constantly updated survival guide for genetic epidemiology. The GenEpi Toolbox. Atherosclerosis 2010; 209(2): 321-35.
161. Woodahl EL, Hingorani SR, Wang J, et al. Pharmacogenomic associations in ABCB1 and CYP3A5 with acute kidney injury and chronic kidney disease after myeloablative hematopoietic cell transplantation. Pharmacogenomics J 2008; 8(4): 248-55.
162. Fu SJ, Wang YB, Yu LX, et al. Factors responsible for interindividual variations in dosage/concentration of tacrolimus in renal transplant recipients. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28(12): 2161-4.
163. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 2010; 55(25): 2804-12.
164. Aidoo M, McElroy PD, Kolczak MS, et al. Tumor necrosis factoralpha promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. Genet Epidemiol 2001; 21(3): 201-11.
165. Nelder J, Wedderburn R. Generalized Linear Models. J Royal Stat Soc 2010; 135(3): 370-84.
166. Kirkwood B, Sterne J. Essentials of Medical Statistics. Malden, MA: Wiley-Blackwell 2001.
167. Huber PJ. Robust Statistics. Wiley 1981.
168. Agresti A. Categorical Data Analysis. New York: John Wiley & Sons 1990.
169. Slinker BK, Glantz SA. Multiple linear regression is a useful alternative to traditional analyses of variance. Am J Physiol 1988; 255(3 Pt 2): R353-R367.
170. Li W, Reich J. A complete enumeration and classification of twolocus disease models 2000.
171. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons Inc 2000.
172. Maxwell SE, Delaney HD. Designing Experiments and Analyzing Data. New Jersey 1990.
173. Cohen J, Cohen P, West SG, et al. Applied Multiple Regression and Correlation Analysis for the Behavioral Sciences. New Jersey: Lawrence Earlbaum Associates. 2003.
174. Ohno-Machado L. Modeling medical prognosis: survival analysis techniques. J Biomed Inform 2001; 34(6): 428-39.
175. Smith M, Kohn R. Nonparametric regression using Bayesian variable selection. J Econom 1996; 75(2): 317-43.
176. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. New York: Springer-Verlag. 2001.
177. Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics 2006; 16(11): 837-45.
178. Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol 2010; 28(5): 237-45.
179. Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63(10 Suppl 4): S3-S8.
180. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human livermicrosomes. J Clin Invest 1998; 101(4): 847-54.
181. Levy G, Weber W. Interindividual Variability in Human Drug Metabolism. New York: Taylor and Francis. 2001.
182. Cordell HJ. Detecting gene-gene interactions that underlie human diseases. Nat Rev Genet 2009; 10(6): 392-404.
183. Motsinger-Reif AA, Reif DM, Fanelli TJ, et al. A comparison of analytical methods for genetic association studies. Genet Epidemiol 2008; 32(8): 767-78.
184. Motsinger AA, Ritchie MD, Reif DM. Novel methods for detecting epistasis in pharmacogenomics studies. Pharmacogenomics 2007; 8(9): 1229-41.
185. Motsinger AA, Ritchie MD. Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics 2006; 2(5): 318-28.
186. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19(3): 376-82.
187. Ritchie MD, Hahn LW, Roodi N, et al. Multifactor-dimensionality reduction reveals high-order interactions among estrogenmetabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69(1): 138-47.
188. Cho YM, Ritchie MD, Moore JH, et al. Multifactor-dimensionality reduction shows a two-locus interaction associated with Type 2 diabetes mellitus. Diabetologia 2004; 47(3): 549-54.
189. Coffey CS, Hebert PR, Ritchie MD, et al. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. BMC Bioinformatics 2004; 5: 49.
190. Cattaert T, Urrea V, Naj AC, et al. FAM-MDR: a flexible familybased multifactor dimensionality reduction technique to detect epistasis using related individuals. PLoS One 2010; 5(4): e10304.
191. Breiman L, Friedman J.H, Olshen R.A, et al. Classification and Regression Trees. New York: Chapman & Hall. 1984.
192. Schwarz DF, Konig IR, Ziegler A. On safari to Random Jungle: a fast implementation of Random Forests for high-dimensional data. Bioinformatics 2010; 26(14): 1752-8.
193. Motsinger AA, Lee SL, Mellick G, et al. GPNN: power studies and applications of a neural network method for detecting gene-gene interactions in studies of human disease. BMC Bioinformatics 2006; 7: 39.
194. Motsinger AA, Reif DM, Dudek SM, et al. Understanding the Evolutionary Process of Grammatical Evolution Neural Networks for Feature Selection in Genetic Epidemiology. Proc IEEE Symp Comput Intell Bioinforma Comput Biol 2006; 2006: 1-8.
195. Ritchie MD, White BC, Parker JS, et al. Optimization of neural network architecture using genetic programming improves detection and modeling of gene-gene interactions in studies of human diseases. BMC Bioinformatics 2003; 4(1): 28.
196. Turner SD, Dudek SM, Ritchie MD. Grammatical Evolution of Neural Networks for Discovering Epistasis among Quantitative Trait Loci. Lect Notes Comput Sci 2010; 6023: 86-97.
197. Friedman JH. Multivariate Adaptive Regression Splines. Ann Stat 1991; 19(1): 1-67.
198. Kooperberg C, Ruczinski I, LeBlanc ML, et al. Sequence analysis using logic regression. Genet Epidemiol 2001; 21(Suppl 1): S626-S631.
199. Kooperberg C, Ruczinski I. Identifying interacting SNPs using Monte Carlo logic regression. Genet Epidemiol 2005; 28(2): 157-70.
200. Breiman L. Random Forests. Mach Learn 2001; 45(1): 5-32.
201. Ritchie MD, Coffey CSMJH. Genetic programming neural networks: A bioinformatics tool for human genetics. Lect Notes Comput Sci 2004; 3102: 438-48.
202. Ayers KL, Cordell HJ. SNP Selection in genome-wide and candidate gene studies via penalized logistic regression. Genet Epidemiol 2010; 34(8): 879-91.
203. Bush WS, Dudek SM, Ritchie MD. Biofilter: a knowledgeintegration system for the multi-locus analysis of genome-wide association studies. Pac Symp Biocomput 2009; 368-79.
204. Chan EK, Hawken R, Reverter A. The combined effect of SNPmarker and phenotype attributes in genome-wide association studies. Anim Genet 2009; 40(2): 149-56.
205. Fong C, Ko DC, Wasnick M, et al. GWAS analyzer: integrating genotype, phenotype and public annotation data for genome-wide association study analysis. Bioinformatics 2010; 26(4): 560-4.
206. Greene CS, Penrod NM, Kiralis J, et al. Spatially Uniform ReliefF (SURF) for computationally-efficient filtering of gene-gene interactions. Bio Data Min 2009; 2(1): 5.
207. Marchini J, Donnelly P, Cardon LR. Genome-wide strategies for detecting multiple loci that influence complex diseases. Nat Genet 2005; 37(4): 413-7.
208. Greene CS, Penrod NM, Williams SM, et al. Failure to replicate a genetic association may provide important clues about genetic architecture. PLoS One 2009; 4(6): e5639.
209. Fisher RA. Statistical Methods and Scientific Inference. New York: Hafner. 1956.
210. Abdi H. Bonferroni and Sidak corrections for multiple comparisons. Thousand Oaks, CA: Sage. 2007.
211. Rice TK, Schork NJ, Rao DC. Methods for handling multiple testing. Adv Genet 2008; 60: 293-308.
212. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc 1995; 57(1): 289-300.
213. Ioannidis JP, Ntzani EE, Trikalinos TA, et al. Replication validity of genetic association studies. Nat Genet 2001; 29(3): 306-9.
214. Ioannidis JP. Non-replication and inconsistency in the genomewide association setting. Hum Hered 2007; 64(4): 203-13.
215. Wasserman NF, Aneas I, Nobrega MA. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. Genome Res 2010; 20(9): 1191-7.
216. Glinskii AB, Ma J, Ma S, et al. Identification of intergenic transregulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle 2009; 8(23): 3925-42.
217. Glinsky GV. SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways. Cell Cycle 2008; 7(22): 3564-76.
218. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9(10): 775-89.
219. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010; 70(18): 7027-30.
220. Mishra PJ, Humeniuk R, Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 2007; 104(33): 13513-8.
221. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. Nat Rev Genet 2009; 10(5): 318-29.
222. Coffey CS, Hebert PR, Krumholz HM, et al. Reporting of model validation procedures in human studies of genetic interactions. Nutrition 2004; 20(1): 69-73.
223. Taniguchi A, Urano W, Tanaka E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 2007; 17(6): 383-90.
224. Grosse SD, Wordsworth S, Payne K. Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 2008; 10(9): 648-54.
225. Langley MR, Booker JK, Evans JP, et al. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn 2009; 11(3): 216-25.
226. Relling MV, Altman RB, Goetz MP, et al. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol 2010; 11(6): 507-9.